(E)-4-morpholino-4-oxobut-2-enoic acid | 167113-72-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-4-morpholino-4-oxobut-2-enoic acid
• 英文别名: (E)-4-(4-morpholinyl)-4-oxo-2-butenoic acid；N-(4-Morpholinyl)-fumaramic acid；4-morpholin-4-yl-4-oxo-but-2-enoic acid；4-(Morpholin-4-yl)-4-oxobut-2-enoic acid；(E)-4-morpholin-4-yl-4-oxobut-2-enoic acid
• CAS: 167113-72-6
• 化学式: C₈H₁₁NO₄
• mdl: MFCD00224188
• 分子量: 185.18
• InChiKey: FCTFTKXWJQFGLI-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-4-morpholino-4-oxobut-2-enoic acid 在 (2S,3R)-3,4-二氢-3-异丙基-2-苯基-2H-嘧啶并[2,1-b]苯并噻唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.5h， 生成 triisopropylsilyl (S)-4-methyl-3-(morpholine-4-carbonyl)-4-nitropentanoate
  参考文献：
  名称：

  使用硝酸甲硅烷基酯催化对映选择性α，β-不饱和酰基铵催化中的未预期甲硅烷基转移。

  摘要：

  据报道，使用磺酸硅烷基酯用于异硫脲催化的γ-硝基取代的甲硅烷基酯的合成，该γ-硝基取代的甲硅烷基酯的产率高，对映选择性高（产率高达93％，er：99：1 er）。在该反应中偶然发现的甲硅烷基酯产物的形成证明了在α，β-不饱和酰基铵催化中催化剂转换的新平台。

  DOI：

  10.1021/acs.orglett.9b04404
• 作为产物：
  描述：

  N-(trans-3-ethoxycarbonylacryloyl)morpholine 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 以55%的产率得到(E)-4-morpholino-4-oxobut-2-enoic acid
  参考文献：
  名称：

  使用硝酸甲硅烷基酯催化对映选择性α，β-不饱和酰基铵催化中的未预期甲硅烷基转移。

  摘要：

  据报道，使用磺酸硅烷基酯用于异硫脲催化的γ-硝基取代的甲硅烷基酯的合成，该γ-硝基取代的甲硅烷基酯的产率高，对映选择性高（产率高达93％，er：99：1 er）。在该反应中偶然发现的甲硅烷基酯产物的形成证明了在α，β-不饱和酰基铵催化中催化剂转换的新平台。

  DOI：

  10.1021/acs.orglett.9b04404

文献信息

• MALEIC ACID DERIVATIVE, PRODUCTION METHOD FOR SAME, AND ANTI-CANCER COMPOSITION COMPRISING SAME
  申请人：Medicinal Bioconvergence Research Center

  公开号：US20160152607A1

  公开（公告）日：2016-06-02

  A maleic acid derivative represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof: wherein, A is 5- to 7-membered phenyl having a substituent group, or heteroaryl or heterocycloalkyl containing at least one heteroatom selected from the group consisting of N, O, and S and having a substituent group, or 5- to 7-membered phenyl, heteroaryl, or heterocycloalkyl linked to C 1 -C 5 straight- or branched-chain alkyl, wherein the substituent group is unsubstituted, halogen, OH, OR 1 , nitro, nitrile, NH 2 , NHR 1 , NR 1 R 2 COOH, COOR 1 , CONH 2 , CONHR 1 , C 1 -C 5 straight- or branched-chain alkyl, phenyl, heteroaryl, or 5- to 7-membered heterocycloalkyl, where R 1 and R 2 each are C 1 -C 5 straight- or branched-chain alkyl, or phenyl or heteroaryl having a substituent group.

  下面化学式1所示的马来酸衍生物或其药学上可接受的盐：其中，A是带有取代基的5-至7-成员苯基，或含有来自N、O和S组成的群中至少一个杂原子的杂芳基或杂环烷基并带有取代基，或与C1-C5直链或支链烷基连接的5-至7-成员苯基、杂芳基或杂环烷基，其中取代基未取代、卤素、OH、OR1、硝基、腈、NH2、NHR1、NR1R2COOH、COOR1、CONH2、CONHR1、C1-C5直链或支链烷基、苯基、杂芳基或5-至7-成员杂环烷基，其中R1和R2各自是C1-C5直链或支链烷基，或带有取代基的苯基或杂芳基。
• Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof
  申请人：Ham Young Jin

  公开号：US20080009509A1

  公开（公告）日：2008-01-10

  The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.

  本发明涉及一种新型的喹唑啉衍生物及其药学上可接受的盐，用于抑制癌细胞的生长，其制备方法以及包含其作为活性成分的制药组合物。
• NOVEL MALEIC ACID DERIVATIVE, PRODUCTION METHOD FOR SAME AND ANTI-CANCER COMPOSITION COMPRISING SAME
  申请人：Medicinal Bioconvergence Research Center

  公开号：EP3006428A1

  公开（公告）日：2016-04-13

  The present invention relates to a novel anticancer composition, and more specifically relates to a maleic acid derivative compound of Chemical Formula 1, to a production method for the compound, and to a pharmaceutical composition comprising the compound. The maleic acid derivative of the present invention suppresses the expression of AIMP2-DX2 and hence selectively suppresses the growth of cancer cell lines without acting on normal cells, and thus pharmaceutical compositions containing the maleic acid derivative of the present invention and pharmaceutically acceptable salts thereof as active ingredients can be used to prevent and treat cancer.

  本发明涉及一种新型抗癌组合物，更具体地说，涉及一种化学式1的马来酸衍生物化合物、该化合物的生产方法以及含有该化合物的药物组合物。本发明的马来酸衍生物可抑制 AIMP2-DX2 的表达，从而选择性地抑制癌细胞株的生长，而不作用于正常细胞，因此含有本发明的马来酸衍生物及其药学上可接受的盐类作为活性成分的药物组合物可用于预防和治疗癌症。
• Design and Synthesis of Renin Inhibitors: Incorporation of Transition-State Isostere Side Chains That Span from the S1 to the S3 Binding Pockets and Examination of P3-Modified Renin Inhibitors
  作者：Aurash Shahripour、James S. Kaltenbronn、Elizabeth A. Lunney、Bruce A. Steinbaugh、James M. Hamby、Harriet W. Hamilton、Tomi K. Sawyer、Christine Humblet、Annette M. Doherty

  DOI：10.1021/jm00015a012

  日期：1995.7

  A series of renin inhibitors were designed to examine the topography of the contiguous binding pocket of renin that is normally occupied by the P1 and P3 side chains. Molecular modeling suggested that extending the P1 hydrophobic side chain into the adjacent hydrophobic S3 enzyme pocket was feasible. Novel transition state isosteres with modified P1-->P3 side chains were synthesized and provided enhanced binding affinity when incorporated into renin inhibitors in which the P3 Phe was substituted by Gly. In a complementary approach, the binding affinities of a variety of P3-P4-modified peptidomimetic renin inhibitors that lacked substantial hydrophobic side chains at these sites were measured.
• QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF
  申请人：Hanmi Pharm. Co., Ltd.

  公开号：EP1844022A1

  公开（公告）日：2007-10-17